Moleculin Biotech holds annual shareholder meeting

• Moleculin Biotech held its annual shareholder meeting on Oct. 9, 2026.
• Shareholders ratified Grant Thornton as independent registered public accounting firm for the year ending Dec. 31, 2026.
• Investors adopted an amendment increasing shares authorized under the 2024 stock plan by 3,861,894 to 3,875,999.
• Advisory approval was given for executive compensation.
• Charter change to remove supermajority amendment thresholds failed; separate charter amendment authorized a potential reverse stock split, ratio 1-for-2 to 1-for-20.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-032455), on October 09, 2026, and is solely responsible for the information contained therein.